Project Grant R01HL178582
Award Date
5/15/25
Completion Date
2/28/29
Dollars Obligated
$496K
Federal Agency
National Heart Lung and Blood Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $106,201 to the University of North Carolina at Chapel Hill (UNC-CH) to support research on post-transcriptional mechanisms regulating direct cardiac reprogramming. The project aims to characterize the mechanisms by which the innovative TBX5+siYBX1 cocktail can reprogram cardiac fibroblasts into induced cardiomyocyte-like cells, as well...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $243,000 in funding to the University of Cincinnati to develop innovative RNA biodevices that integrate CRISPR and ADAR gene-editing technologies. The goal is to enhance the efficiency and specificity of converting fibroblasts into cardiac cells for in vivo reprogramming strategies to address excessive fibrosis and heart failure following...
The federal Project Grant award R01HL174940, totaling $785,198, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research grant program (CFDA 93.837). The grant supports research to investigate the role of chaperone-mediated autophagy (CMA) in regulating the function and phenotypic transitions of fibroblasts and myofibroblasts during cardiac tissue repair and remodeling following myocardial infarction. The project aims to study how CMA...
This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a comprehensive research project to investigate the development of diverse cardiac cell types and their organization into heart structures. The $1,451,467 award, with a project period from July 1, 2024 to June 30, 2028, will be performed by the University of California, San Diego (UCSD). The research aims to identify and examine...
The federal Project Grant award R01HL177462, with total funding of $540,856, was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to identify transcriptional regulators of endocardial-restricted gene expression, determine how valve-restricted gene expression is achieved, and define the regulation and function of the SLC16A2 gene during heart injury and regeneration. The research aims...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,249,307 to support research aimed at understanding and overcoming the immaturity of pluripotent stem cell-derived cardiomyocytes (PSC-CMs). The project seeks to identify critical gene regulatory networks underlying the premature arrest of PSC-CM maturation, with the goal of developing transcriptome-based strategies to improve the...
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $751,747 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of North Carolina at Chapel Hill (UNC-CH). The grant, effective January 1, 2025 through November 30, 2028, will support research on the regulation of cardiomyocyte (heart muscle cell) maturation by the enzyme CARM1. The project aims to define the critical role of CARM1 in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, will investigate the Hippo-YAP signaling pathway and its role in promoting cardiac regenerative repair following myocardial infarction. The total funding amount is $693,261, with an award date of January 10, 2025 and an ultimate completion date of December 31, 2028. The primary objectives are to gain insights into gene therapy strategies...
This federal Project Grant award R01HL173366, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to elucidate the molecular mechanisms regulating the dynamic interplay between myocardial cell-cell and cell-extracellular matrix interactions, and how these signals control cardiomyocyte proliferation. The $601,507 award, granted on January 1, 2025, supports preclinical proof-of-concept studies to determine whether...